Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

107.80 +1.62 (+1.53%)
Streaming Delayed Price Updated: 3:05 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Black Friday On Wall Street: 10 S&P 500 Stocks Trading At 40%+ Discount From Analysts' Expectations
Several S&P 500 stocks are trading at discounts of over 40% compared to analysts' price targets, offering potential upside, but caution is needed. 
Via Benzinga
Topics Stocks
Exposures US Equities
$100 Invested In Moderna 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Big Players' Recent Trades in MRNA Options
Via Benzinga
3 Biotech Stocks That Could Be Millionaire Makers
Many biotech stocks offer exciting long-term growth prospects. 
Via The Motley Fool
Half Of S&P 500 Stocks Still Below 200-Day Average, Ignoring Covid-Like Rally: 10 Bargain Plays For Latecomer Bulls
Explore the dichotomy in the latest S&P 500 rally: Strong overall performance masks the underperformance of nearly half its stocks. 
Via Benzinga
Topics Stocks
Exposures US Equities
Big Players' Recent Trades in MRNA Options
Via Benzinga
Peering Into Moderna's Recent Short Interest
Via Benzinga
Why Is COVID-19 Vaccine Maker Moderna Stock Trading Lower Today?
Moderna Inc (NASDAQ: MRNA) shares slipped on Tuesday trading after the European Patent Office said a contested mRNA patent owned by Moderna is invalid, marking a victory for Pfizer Inc (NYSE: PFE) /  
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Don’t Let the Q3 Earnings Miss Keep You From These 3 Stocks!
Few S&P 500 companies didn’t meet or exceed Q3 2023 earnings estimates. Here are three earnings miss investment opportunities. 
Via InvestorPlace
Topics Earnings Stocks
Exposures Financial US Equities
Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
Via ACCESSWIRE
3 Cathie Wood Bargain Buys That Should Be on Your List Too
Wood just picked up shares of these companies recently. 
Via The Motley Fool
Where Will Novavax Be in 3 Years?
Novavax shares have plunged from early pandemic highs. 
Via The Motley Fool
2 Top Biotech Stocks to Buy Right Now
Don't give up on these stocks too fast. 
Via The Motley Fool
Moderna to Present at Upcoming Conferences in November 2023
Via ACCESSWIRE
Moderna Unusual Options Activity For November 08
Via Benzinga
Moderna Highlights its Digital and AI Strategy and Progress at Second Digital Investor Event
Via ACCESSWIRE
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Moderna Stock Was Cratering This Week
Perhaps the COVID-19 vaccine developer's best days are in the past. 
Via The Motley Fool
Exposures COVID-19
Moderna's Stock Just Tumbled 12%. Here's Why It's Still a Buy.
It's gearing up for its next growth spurt. 
Via The Motley Fool
6 Nasdaq 100 Stocks Down 40% or More that Will Soar As Much 367%
Wall Street is forever optimistic about the future for stocks and pegs these seven Nasdaq 100 stocks as ready for supersonic growth 
Via InvestorPlace
High Risk Alert: 7 Vulnerable Stocks to Dump Now
The economy is showing weakness. These seven stocks at risk could be at the center of the coming bust. 
Via InvestorPlace
Topics Economy
Exposures Economy
Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year
Via ACCESSWIRE
BioNTech Shifted Its Focus To Innovative Oncology And Mainz Biomed Announced A Showcasing Of Its Revolutionary Colorectal Cancer Detection Test
On November 6th, BioNTech SE (NASADQ: SE) who partnered with Pfizer Inc (NYSE: PFE) in the making of a blockbuster COVID-19 vaccine, posted a surprise earnings with its latest quarterly report. 
Via Benzinga
Exposures COVID-19
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks This Year?
Should you buy the dip on these S&P 500 stocks? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Cathie Wood Just Bought This Struggling Stock After Its Billion-Dollar Quarterly Loss. Should You?
This particular stock has dropped more than 50% this year. 
Via The Motley Fool
Like Moderna, BioNTech Cuts Annual Sales Forecast By 20% As Pandemic Fades
BioNTech SE (NASDAQ: BNTX) has reported Q3 revenues of €895.3 million ($974.49 million), sharply down from €3.461 billion a year ago. 
Via Benzinga
Down 84% From Its Peak. Is It Finally Time to Buy Moderna?
The vaccine developer's huge profits have turned into heavy losses. 
Via The Motley Fool
Moderna May Be Facing Its Toughest Moment Ever. Time to Sell?
Moderna still has big ambitions -- beyond the coronavirus vaccine -- that could pay off in a few years. 
Via The Motley Fool
Exposures COVID-19
These Analysts Cut Their Forecasts On Moderna After Q3 Results
Moderna Inc (NASDAQ: MRNA) posted a loss for the third quarter on Thursday. 
Via Benzinga
Cyberark Software To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.